| Nov 19 |
RVPH: Year-End OLE Update
|
| Nov 15 |
Reviva Pharmaceuticals reports Q3 results
|
| Nov 14 |
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 12 |
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
|
| Nov 6 |
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
|
| Oct 31 |
Reviva to Participate in the UBS Global Healthcare Conference
|
| Oct 8 |
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Oct 2 |
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
| Sep 26 |
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
|
| Sep 16 |
RVPH: RECOVER Biomarker KOL Event
|
